loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ataluren

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ataluren

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 30,663Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PTC Therapeutics Reports Q2 2024 Results And Corporate Update
    PTC Therapeutics Reports Q2 2024 Results And Corporate Update

    08 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-second-quarter-2024-financial-results-302218200.html

    PR NEWSWIRE
    08 Aug 2024
    Share Share
    EMA committee recommends non-renewal conditional marketing authorisation of DMD
    EMA committee recommends non-renewal conditional marketing authorisation of DMD

    12 Jul 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=171262&sid=2

    PHARMABIZ
    12 Jul 2024
    Share Share
    CHMP Issues Negative Opinion On Translarna Following European Commission Review
    CHMP Issues Negative Opinion On Translarna Following European Commission Review

    28 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chmp-issues-negative-opinion-on-translarna-following-european-commission-request-for-review-302185263.html

    PR NEWSWIRE
    28 Jun 2024
    Share Share
    PTC's re-examination bid for Translarna falls short in Europe
    PTC's re-examination bid for Translarna falls short in Europe

    25 Jan 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ptcs-re-examination-bid-dmd-drug-translarna-falls-short-europe

    FIERCE PHARMA
    25 Jan 2024
    Share Share
    EMA recommends non-renewal of authorisation of medicine Translarna
    EMA recommends non-renewal of authorisation of medicine Translarna

    15 Sep 2023

    // EMA

    https://www.ema.europa.eu/en/news/ema-recommends-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine-translarna

    EMA
    15 Sep 2023
    Share Share
    NICE signs off on rare disease therapies from Alnylam, PTC
    NICE signs off on rare disease therapies from Alnylam, PTC

    20 Jan 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/nice-recommends-two-rare-disease-therapies-ptc-therapeutics-and-alnylam

    Zoey Becker FIERCE PHARMA
    20 Jan 2023
    Share Share